<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="163020">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01760096</url>
  </required_header>
  <id_info>
    <org_study_id>PNH-2013</org_study_id>
    <nct_id>NCT01760096</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013)</brief_title>
  <official_title>Phase II Study of the Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Hematology &amp; Blood Diseases Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Hematology &amp; Blood Diseases Hospital</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Paroxysmal nocturnal hemoglobinuria is an acquired chronic hemolytic anemia,this study is
      designed to evaluate the safety and efficacy of Levamisole combined with cyclosporine A in
      patients with Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the setting of
      another bone marrow  failure syndromes
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal disorder of the
      hematopoietic stem cell characterized by intravascular hemolysis, hemoglobinuria, anemia,
      and thrombosis, Patients may be at high risk of thrombosis and may develop bone marrow
      failure or aplastic anemia, with low white blood cell and platelet counts,because the
      manifestation and pathologic processes are complicate,the treatment is very difficult,this
      study is designed to evaluate the safety and efficacy of Levamisole combined with
      cyclosporine A in patients with Subclinical Paroxysmal Nocturnal Hemoglobinuria and  PNH in
      the setting of another bone marrow  failure syndromes
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of patients in each group in complete or partial remission</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>she got blood transfusion-independent,the hemoglobin became higher</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Paroxysmal Nocturnal Hemoglobinuria</condition>
  <condition>Hemoglobinuria</condition>
  <condition>Hemoglobinuria, Paroxysmal</condition>
  <condition>Proteinuria</condition>
  <condition>Urination Disorders</condition>
  <condition>Thrombosis</condition>
  <condition>Bone Marrow Failure</condition>
  <condition>Aplastic Anemia,</condition>
  <condition>Anemia, Hemolytic</condition>
  <arm_group>
    <arm_group_label>Levamisole+cyclosporin A+Glucocorticoids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levamisole+cyclosporin A+Glucocorticoids</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cyclosporin A+Glucocorticoids</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>cyclosporin A+Glucocorticoids</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucocorticoids</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glucocorticoids</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levamisole+cyclosporin A+Glucocorticoids</intervention_name>
    <description>Levamisole 2.5mg/kg every other day cyclosporin A 3-5mg/kg every other day Glucocorticoids0.25 mg/kg every day(prednisone)</description>
    <arm_group_label>Levamisole+cyclosporin A+Glucocorticoids</arm_group_label>
    <other_name>Levamisole</other_name>
    <other_name>cyclosporin A</other_name>
    <other_name>Glucocorticoids</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporin A+Glucocorticoids</intervention_name>
    <description>cyclosporin A 3-5mg/kg every day Glucocorticoids0.25mg/kg every day(prednisone)</description>
    <arm_group_label>cyclosporin A+Glucocorticoids</arm_group_label>
    <other_name>cyclosporin A</other_name>
    <other_name>Glucocorticoids</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucocorticoids</intervention_name>
    <description>Glucocorticoids0.25mg/kg every day(prednisone)</description>
    <arm_group_label>Glucocorticoids</arm_group_label>
    <other_name>Glucocorticoids</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Clinical and biochemical signs of Subclinical Paroxysmal Nocturnal Hemoglobinuria and
             PNH in the setting of another bone marrow  failure syndromes

          2. Diagnosis confirmed by Ham's test or Flow cytometry Patients have any Flow cytometry
             data

          3. patient should complete levamisole study for at least half a year

        Exclusion Criteria:

          1. Active infection which requires antibiotic treatment

          2. Pregnant or lactating women

          3. Epilepsy and mental illness

          4. Kidney and liver function abnormal
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>yizhou zheng, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Hematology &amp; Blood Diseases Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Hematology &amp; Blood Diseases Hospital,</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.chinablood.com.cn</url>
    <description>CBD</description>
  </link>
  <reference>
    <citation>Parker C, Omine M, Richards S, Nishimura J, Bessler M, Ware R, Hillmen P, Luzzatto L, Young N, Kinoshita T, Rosse W, Soci√© G; International PNH Interest Group. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005 Dec 1;106(12):3699-709. Epub 2005 Jul 28. Review.</citation>
    <PMID>16051736</PMID>
  </reference>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 1, 2013</lastchanged_date>
  <firstreceived_date>January 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute of Hematology &amp; Blood Diseases Hospital</investigator_affiliation>
    <investigator_full_name>Yizhou Zheng</investigator_full_name>
    <investigator_title>Vice director of the therapeutic centre of anemic diseases</investigator_title>
  </responsible_party>
  <keyword>Paroxysmal Nocturnal Hemoglobinuria</keyword>
  <keyword>Anemia</keyword>
  <keyword>Hematologic Diseases</keyword>
  <keyword>bone marrow failure</keyword>
  <keyword>Immunologic Factors</keyword>
  <keyword>Physiological Effects of Drugs</keyword>
  <keyword>Levamisole</keyword>
  <keyword>cyclosporine A</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
    <mesh_term>Anemia, Hemolytic</mesh_term>
    <mesh_term>Hemoglobinuria</mesh_term>
    <mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
    <mesh_term>Pancytopenia</mesh_term>
    <mesh_term>Proteinuria</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Urination Disorders</mesh_term>
    <mesh_term>Hemolysis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Levamisole</mesh_term>
    <mesh_term>Glucocorticoids</mesh_term>
    <mesh_term>Physiological Effects of Drugs</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
